Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/1997

01-06-1997 | ORIGINAL ARTICLE

Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center

Authors: Naoto T. Ueno, Aman U. Buzdar, Sonja E. Singletary, Frederick C. Ames, Marsha D. McNeese, Frankie A. Holmes, Richard L. Theriault, Eric A. Strom, Barbara J. Wasaff, Lina Asmar, Debbie Frye, Gabriel N. Hortobagyi

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/1997

Login to get access
Metadata
Title
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center
Authors
Naoto T. Ueno
Aman U. Buzdar
Sonja E. Singletary
Frederick C. Ames
Marsha D. McNeese
Frankie A. Holmes
Richard L. Theriault
Eric A. Strom
Barbara J. Wasaff
Lina Asmar
Debbie Frye
Gabriel N. Hortobagyi
Publication date
01-06-1997
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/1997
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050664

Other articles of this Issue 4/1997

Cancer Chemotherapy and Pharmacology 4/1997 Go to the issue

CLINICAL TRIAL REPORT

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

ORIGINAL ARTICLE

Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods

ORIGINAL ARTICLE

The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue

ORIGINAL ARTICLE

Bladder tissue pharmacokinetics of intravesical taxol

SHORT COMMUNICATION

Adriamycin-induced histamine release from heart tissue in vitro

ORIGINAL ARTICLE

Measurement of nitrobenzylthioinosine in plasma and erythrocytes: a pharmacokinetic study in mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits